AR035879A1 - Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienen - Google Patents
Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienenInfo
- Publication number
- AR035879A1 AR035879A1 ARP020101681A ARP020101681A AR035879A1 AR 035879 A1 AR035879 A1 AR 035879A1 AR P020101681 A ARP020101681 A AR P020101681A AR P020101681 A ARP020101681 A AR P020101681A AR 035879 A1 AR035879 A1 AR 035879A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- halogen
- nitrogen atom
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 208000037803 restenosis Diseases 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000003120 Angiofibroma Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000022461 Glomerular disease Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010038563 Reocclusion Diseases 0.000 abstract 1
- 206010064127 Solar lentigo Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- 201000011066 hemangioma Diseases 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 201000009925 nephrosclerosis Diseases 0.000 abstract 1
- 210000000944 nerve tissue Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Structural Engineering (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
Abstract
Derivados de cianoantranilamida de fórmula general (1), en donde A representa el grupo -N(R7)-; W es oxígeno, azufre, dos átomos de hidrógeno o el grupo -N(R8)-; Z es una unión, el grupo -N(R10)- ó =N-, alquilo C1-12 ramificado o no ramificado o el grupo -(CRaRb)m(CRcRd)n(CReRf)o-; m, n y o son 0-3; Ra, Rb, Rc, Rd, Re, Rf, son, independientemente entre sí, hidrógeno, flúor, alquilo C1-4 o el grupo -N(R11)- y/o Ra y/o Rb con Rc y/o Rd o Rc con Re y/o Rf pueden formar una unión, o hasta dos de los radicales Ra-Rf pueden formar un puente, cada uno de ellos con hasta 3 átomos de C hacia R1 o hacia R7; X es alquilo C1-6; R1 es alquilo C1-12 o alquenilo C2-12 ramificado o no ramificado, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, alquiloxi C1-6, aralquiloxi, alquilo C1-6 y/o por el grupo NR12R13, o es cicloalquilo C3-10 o cicloalquenilo C3-10, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, alquiloxi C1-6, alquilo C1-6 y/o por el grupo NR12R13, o es arilo o hetarilo, que puede ser mono- o polisustituido de modo igual o diferente por halógeno, hidroxi, alquiloxi C1-6, aralquiloxi, alquilo C1-6, haloalquilo C1-6, cianoalquilo C1-6 o por el grupo =O, -OR14 ó -R14; Y1 a Y5 son, cada uno, un átomo de nitrógeno o el grupo -CY6; Y6 es ciano, halógeno, alquilo C1-6, alcoxi C1-6, amino o hidroxi, donde el anillo contiene por lo menos un átomo de nitrógeno y el anillo contiene por lo menos un radical ciano; D es un átomo de nitrógeno o el grupo C-R3; E es un átomo de nitrógeno o el grupo C-R4; F es un átomo de nitrógeno o el grupo C-R5; G es un átomo de nitrógeno o el grupo C-R6; donde R3, R4, R5 y R6 son hidrógeno, halógeno o alcoxi C1-6, alquilo C1-6 o carboxialquilo C1-6 no sustituido o en caso dado, mono- o polisustituido por halógeno; R7 es hidrógeno o alquilo C1-6 o forma un puente con Ra-Rf desde Z o hacia R1 con hasta 3 miembros de anillo; R8, R9, R10 y R11 son hidrógeno o alquilo C1-6; R12 y R13 son hidrógeno, alquilo C1-6 o forman un anillo que puede contener otro heteroátomo; R14 es el grupo alquilo C1-15-R15, donde el radical alquilo puede estar interrumpido una o varias veces por oxígeno o el grupo (CH2-CH2-O)u(CH2)v-R15; R15 es arilo, hetarilo, alquilo C1-6, aralquilo, -CH2CN o el grupo NR16R17; R16 y R17 son hidrógeno, alquilo C1-6, acilo C1-6 o forman un anillo que puede contener otro heteroátomo; u y v son 0-5; y sus isómeros, enantiómeros y sales. Estos compuestos son identificados como inhibidores de la tirosinakinasa KDR y FLT, y son particularmente apropiados para el tratamiento de aquellas enfermedades que son originadas o estimuladas por la angiogénesis persistente provocada por el receptor VEGF o un aumento de la permeabilidad vascular. Medicamentos que contienen al menos un compuesto de fórmula (1), y el uso de estos compuestos para preparar un medicamento destinado al tratamiento de psoriasis, sarcoma de Kaposi, restenosis tal como, por ejemplo, la restenosis inducida por stent, endometriosis, mal de Crohn, enfermedad de Hodkin, leucemia, artritis tal como la artritis reumatoide, hemangioma, angiofibroma, enfermedades oculares tal como la retinopatía diabética, el glaucoma neovascular, enfermedade renales tal como la glomerulonefritis, nefropatía diabética, nefroesclerosis maligna, síndromes microangiopáticos trómbicos, rechazos de transplantes y glomerulopatía, enfermedades fibróticas como cirrosis hepática, enfermedades proliferativas de celulas masangiales, ateroesclerosis, lesiones del tejido nervioso, inhibición de la reoclusión de vasos después de cateterismo con globo dilatable, a la colocación de prótesis vasculares o de dispositivos mecánicos para mantener abiertos los vasos como, por ejemplo, stents, a actuar como inmunosupresores y a favorecer la curación de heridas sin dejar cicatriz, y a los casos de léntigo senil y dermatitis de contacto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001123587 DE10123587B4 (de) | 2001-05-08 | 2001-05-08 | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
| DE2001125295 DE10125295A1 (de) | 2001-05-15 | 2001-05-15 | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035879A1 true AR035879A1 (es) | 2004-07-21 |
Family
ID=26009296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101681A AR035879A1 (es) | 2001-05-08 | 2002-05-08 | Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7429592B2 (es) |
| EP (1) | EP1387838B1 (es) |
| JP (1) | JP4343681B2 (es) |
| AR (1) | AR035879A1 (es) |
| AT (1) | ATE323694T1 (es) |
| CY (1) | CY1105140T1 (es) |
| DE (1) | DE50206476D1 (es) |
| DK (1) | DK1387838T3 (es) |
| ES (1) | ES2261693T3 (es) |
| PE (1) | PE20030037A1 (es) |
| PT (1) | PT1387838E (es) |
| TW (1) | TWI251593B (es) |
| WO (1) | WO2003000678A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| BR0209485A (pt) * | 2001-05-08 | 2004-07-06 | Schering Ag | Antranilamidapiridinamidas seletivas como inibidores vegfr-2 e vegfr-3 |
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US20110142839A1 (en) * | 2008-05-30 | 2011-06-16 | Vegenics Limited | Treatment of pulmonary edema |
| US8350026B2 (en) | 2008-08-27 | 2013-01-08 | Leo Pharma A/S | VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| EP2957283B1 (de) | 2014-06-19 | 2022-12-21 | Symrise AG | Verfahren zur Identifizierung von Medikamenten zur Beschleunigung der Wundheilung |
| WO2022111793A1 (en) | 2020-11-24 | 2022-06-02 | Symrise Ag | Medicament for accelerated wound healing |
| CN112675173B (zh) * | 2020-12-25 | 2022-04-05 | 华南理工大学 | FXIa抑制剂化合物或其盐的医药用途 |
| WO2022161593A1 (en) | 2021-01-26 | 2022-08-04 | Symrise Ag | Medicament for accelerated wound healing |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6910994A (en) | 1993-05-14 | 1994-12-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity |
| ES2101421T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| DE19910396C2 (de) | 1999-03-03 | 2001-12-13 | Schering Ag | Anthranilsäureamide und deren Verwendung als Arzneimittel |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
-
2002
- 2002-05-03 WO PCT/EP2002/004921 patent/WO2003000678A1/de not_active Ceased
- 2002-05-03 US US10/476,761 patent/US7429592B2/en not_active Expired - Fee Related
- 2002-05-03 ES ES02748691T patent/ES2261693T3/es not_active Expired - Lifetime
- 2002-05-03 PT PT02748691T patent/PT1387838E/pt unknown
- 2002-05-03 DE DE50206476T patent/DE50206476D1/de not_active Expired - Fee Related
- 2002-05-03 JP JP2003507082A patent/JP4343681B2/ja not_active Expired - Fee Related
- 2002-05-03 AT AT02748691T patent/ATE323694T1/de not_active IP Right Cessation
- 2002-05-03 DK DK02748691T patent/DK1387838T3/da active
- 2002-05-03 EP EP02748691A patent/EP1387838B1/de not_active Expired - Lifetime
- 2002-05-08 AR ARP020101681A patent/AR035879A1/es unknown
- 2002-05-08 PE PE2002000386A patent/PE20030037A1/es not_active Application Discontinuation
- 2002-05-08 TW TW091109572A patent/TWI251593B/zh not_active IP Right Cessation
-
2006
- 2006-07-18 CY CY20061100997T patent/CY1105140T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE323694T1 (de) | 2006-05-15 |
| ES2261693T3 (es) | 2006-11-16 |
| DK1387838T3 (da) | 2006-08-14 |
| US7429592B2 (en) | 2008-09-30 |
| EP1387838A1 (de) | 2004-02-11 |
| US20040266770A1 (en) | 2004-12-30 |
| DE50206476D1 (de) | 2006-05-24 |
| PT1387838E (pt) | 2006-08-31 |
| JP2004532281A (ja) | 2004-10-21 |
| TWI251593B (en) | 2006-03-21 |
| EP1387838B1 (de) | 2006-04-19 |
| WO2003000678A1 (de) | 2003-01-03 |
| JP4343681B2 (ja) | 2009-10-14 |
| CY1105140T1 (el) | 2010-03-03 |
| PE20030037A1 (es) | 2003-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035879A1 (es) | Derivados de cianoantranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
| AR035877A1 (es) | Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
| CA2787121C (en) | Aminopyridine derivatives as anti-malarial agents | |
| MY141597A (en) | 2,4-disubstituted thiazolyl derivatives | |
| AR054127A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
| PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
| ZA200603474B (en) | Alkoxy substituted imidazoquinolines | |
| NO20023218L (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
| RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
| EA200800815A1 (ru) | 2-анилин-4-арилзамещенные тиазольные производные | |
| ATE312826T1 (de) | 4,5-disubstituierte 2-aminopyrimidine | |
| CO5580770A2 (es) | Compuestos de quinolina terapeuticos con propiedades antagonistas de 5-ht | |
| CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| ES2564010T3 (es) | Composición farmacéutica para tratar o prevenir el glaucoma | |
| EA023998B1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
| RU2010154425A (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
| AR049696A1 (es) | Derivados de indol | |
| BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos | |
| AR045006A1 (es) | Derivados de quinazolinona 5-sustituidos | |
| NO930499L (no) | Benzimidazolderivater, fremgangsmaate for deres fremstilling og deres anvendelse | |
| KR970003440A (ko) | 삼환 5,6-디하이드로-9H-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-α]피리딘 | |
| AR035465A1 (es) | Compuestos de imidazopiridina, procesos para su preparacion,formulacion farmaceutica, usos de estos compuestos para la fabricacion de medicamentos e intermediarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |